Summary
RVTY Chart
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity, Inc. (RVTY) Q1 2025 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q1 2025 Earnings Conference Call April 28, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Catherine Schulte - Baird Daniel Arias - Stifel Dan Leonard - UBS Luke Sergott - Barclays Tycho Peterson - Jefferies Operator Welcome everyone to Q1 2025 Revvity Earnings Conference Call. My name is Sammy, and I will be coordinating your call today.
Revvity Inc. Dividends
 RVTY In 1 weeks Estimated | Quarterly | $0.07 Per Share |
| RVTY 2 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 5 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 8 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 11 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 18 Apr 2024 Paid | Quarterly | $0.07 Per Share |
Revvity Inc. Earnings
| 28 Jul 2025 (In 3 weeks) Date | | 1.14 Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | 1.38 Cons. EPS | 1.42 EPS |
| 28 Oct 2024 Date | | 1.13 Cons. EPS | 1.28 EPS |
| 30 Jul 2024 Date | | 1.13 Cons. EPS | - EPS |
| RVTY In 1 weeks Estimated | Quarterly | $0.07 Per Share |
| RVTY 2 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 5 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 8 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 11 months ago Paid | Quarterly | $0.07 Per Share |
| RVTY 18 Apr 2024 Paid | Quarterly | $0.07 Per Share |
| 28 Jul 2025 (In 3 weeks) Date | | 1.14 Cons. EPS | - EPS |
| 28 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | 1.38 Cons. EPS | 1.42 EPS |
| 28 Oct 2024 Date | | 1.13 Cons. EPS | 1.28 EPS |
| 30 Jul 2024 Date | | 1.13 Cons. EPS | - EPS |
Revvity Inc. (RVTY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Revvity Inc. ever had a stock split?
Revvity Inc. Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | Prahlad R. Singh CEO | NYSE Exchange | 714046109 Cusip |
| US Country | 11,000 Employees | - Last Dividend | 4 Jun 2001 Last Split | - IPO Date |
Overview
Revvity, Inc., previously known as PerkinElmer, Inc., marks a significant name in the health sciences industry, offering comprehensive solutions, technologies, and services across the globe, including the Americas, Europe, Asia, and other international territories. With its inception in 1937 and headquarters in Waltham, Massachusetts, Revvity has grown to serve an expansive range of clients, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. Operating through two main segments - Life Sciences and Diagnostics - Revvity, Inc. brings forward a suite of instruments, reagents, informatics, software, and much more, catering to a wide array of testing, screening, and research needs in the health sciences sector.
Products and Services
Revvity, Inc.'s product portfolio and services are vast, covering various needs within the life sciences and diagnostics fields. Here's an overview of their most notable offerings:
- AutoDELFIA, BACS-on-Beads, BIOCHIPs, and similar products: These are used for the testing and screening of genetic abnormalities, disorders, and diseases. They serve a critical role in early detection and screening processes for conditions such as down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions.
- chemagic, Chitas, DELFIA, DELFIA Xpress, and related instruments: These instruments and technologies are essential for genomic workflows, supporting applications in oncology, immunodiagnostics, drug discovery, and more. They provide the necessary tools for researchers and healthcare practitioners to analyze and understand genetic material and protein interactions.
- JANUS, LabChip, LifeCycle, LimsLink, and similar software and systems: Key in informatics and laboratory management, these software solutions and systems optimize the operations within laboratories, improving efficiency, data management, and processing in research and diagnostic settings.
- Migele, MultiPROBE, NEXTFLEX, NextPrep, and other reagents and assay platforms: These products are designed for specific applications within the fields of diagnostics and life sciences research, including DNA sequencing, protein analysis, and more. They are integral to the processes of detecting, analyzing, and understanding complex biological materials.
- T-SPOT, Twister, VariSpec, ViaCord, VICTOR 2D, Zephyr, and more brand names: Under these brand names, Revvity, Inc. offers a diverse range of products that cater to different aspects of health sciences, from diagnostic tests for infectious diseases to advanced instruments for genetic and proteomic research. Each brand specializes in a unique area of the health sciences, providing specialized tools and technologies to their respective fields.
Contact Information
